| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development. | Oncotarget | 2015 | 0.81 |
| 2 | miR186 suppresses prostate cancer progression by targeting Twist1. | Oncotarget | 2016 | 0.80 |
| 3 | SUMOylation of TARBP2 regulates miRNA/siRNA efficiency. | Nat Commun | 2015 | 0.78 |